

Trupta Purohit

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7514677/trupta-purohit-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

972
citations

10
h-index

17
g-index

17
ext. papers

1,196
ext. citations

8.4
avg, IF

3.36
L-index

#	Paper	IF	Citations
17	Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity. <i>Nature Communications</i> , 2021 , 12, 2792	17.4	4
16	Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. <i>Nature Chemical Biology</i> , 2021 , 17, 784-793	11.7	7
15	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. <i>Journal of Clinical Investigation</i> , 2020 , 130, 981-997	15.9	72
14	Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations. <i>Blood</i> , 2020 , 136, 2958-2963	2.2	5
13	Covalent and noncovalent constraints yield a figure eight-like conformation of a peptide inhibiting the menin-MLL interaction. <i>European Journal of Medicinal Chemistry</i> , 2020 , 207, 112748	6.8	4
12	Covalent inhibition of NSD1 histone methyltransferase. <i>Nature Chemical Biology</i> , 2020 , 16, 1403-1410	11.7	23
11	Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 4832-4850	8.3	36
10	Theoretical models of inhibitory activity for inhibitors of protein-protein interactions: targeting menin-mixed lineage leukemia with small molecules. <i>MedChemComm</i> , 2017 , 8, 2216-2227	5	6
9	Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL). <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 892-913	8.3	47
8	Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. <i>Cancer Cell</i> , 2015 , 27, 589-602	24.3	212
7	Rational Design of Orthogonal Multipolar Interactions with Fluorine in Protein-Ligand Complexes. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7465-74	8.3	52
6	High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 1543-56	8.3	69
5	The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV. <i>Blood</i> , 2014 , 124, 3730-7	2.2	27
4	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. <i>Blood</i> , 2012 , 120, 4461-9	2.2	134
3	Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. <i>Nature Chemical Biology</i> , 2012 , 8, 277-84	11.7	273
2	Targeting Menin-MLL Interaction to Inhibit MLL Fusion Oncoproteins in Leukemia. <i>Blood</i> , 2011 , 118, 2497-2497		
1	Targeting LEDGF Interactions in MLL Leukemia. <i>Blood</i> , 2011 , 118, 2500-2500	2.2	

